MedTrace Logo

Sleep and Daytime Use of Humidified Nasal High-flow Oxygen in COPD Outpatients

NCT03221387 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-06-07

Study results available
· View outcomes & findings →

Summary

Humidified Nasal High-flow with Oxygen (HNHF-O2) therapy has been reported to have acute beneficial effects in patients with hypoxemic respiratory failure who have been hospitalized. The usefulness of this therapy in the outpatient setting is unproven. This pilot study will test the feasibility of using this therapy in the outpatient setting and its effects on sleep.

Conditions

  • Pulmonary Disease, Chronic Obstructive
  • Hypercapnia
  • Hypoxia

Interventions

DEVICE

Humidified nasal high flow with oxygen

The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.

Sponsors & Collaborators

  • Fisher and Paykel Healthcare

    collaborator INDUSTRY

  • Temple University

    lead OTHER

Principal Investigators

  • Gerard J Criner, MD · Temple University Lewis Katz School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-10
Primary Completion
2019-12-15
Completion
2019-12-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03221387 on ClinicalTrials.gov